Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.

EMBO Mol Med · 2021 · PMC8261516 · PMID 34125494

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the resected orthotopic EMT6/CDDP murine breast cancer model, adjuvant CVX‐241 therapy also showed a trend of increasing median OS—performing better than a PD‐L1 immune checkpoint inhibitor.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.